[关键词]
[摘要]
随着近视患病率的不断攀升，近视相关视力损害及其防控日益成为社会关注的焦点。目前主要的近视控制方法包括阿托品、角膜塑形镜、双焦角膜接触镜、多焦角膜接触镜和功能框架眼镜等。近年来，低浓度阿托品(0.01%、0.05%)成为有效控制近视发生和进展的一线用药。同时低浓度阿托品比高浓度阿托品疗效更加持久，副作用更少见，患者的接受度更高。现本文对低浓度阿托品延缓近视进展的临床研究作一综述，从有效性、安全性、使用时机、联合控制效果等方面进行归纳总结，以期为临床使用低浓度阿托品控制近视提供依据。
[Key word]
[Abstract]
As the prevalence of myopia continues to increase, our society shows increasing interest in the visual impairment associated with myopia and methods for myopia control. Current methods for myopia control include atropine, orthokeratology, dual-focus contact lenses, multifocal contact lenses, and functional frame glasses, etc. Low-concentration atropine(0.01%, 0.05%)became the first-line medication which has been administrated and shown to be effective in controlling the occurrence and progression of myopia. Meanwhile, low-concentration atropine shows longer-lasting effects, less frequent adverse effects and higher patients' acceptance than high-concentration atropine. This article reviews the efficacy, safety, time-to-treatment, and effects when combined with other treatments to provide evidence for the clinical application of low-concentration atropine on myopia control.
[中图分类号]
[基金项目]
陕西省重点研发计划项目(No.2018SF-216); 西安市科技计划项目\〖No.201805097YX5SF31(2)\〗
